Somatostatin analog octreotide LAR^® in gastro–entero–pancreatic tumors

References

• Yao JC, Hassan M, Phan A et al. One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J. Clin. Oncol.26, 3063–3072 (2008).
   PubMed Web of Science ®Google Scholar
• Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev.25, 458–511 (2004).
   PubMed Web of Science ®Google Scholar
• Janson ET, Oberg K. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment. Cancer Chemother. Biol. Response Modif.21, 535–546 (2003).
   PubMedGoogle Scholar
• Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann. Oncol.12(Suppl. 2), S31–S36 (2001).
   PubMed Web of Science ®Google Scholar
• Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med.28, 836–846 (2001).
   PubMedGoogle Scholar
• Reubi JC, Kappeler A, Waser B et al. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. J. Clin. Endocrinol. Metab.83, 3746–3749 (1998).
   PubMedGoogle Scholar
• Patel YC. Somatostatin and its receptor family. Front. Neuroendocrinol.20, 157–198 (1999).
   PubMed Web of Science ®Google Scholar
• Shimon I, Taylor JE, Dong JZ et al. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. J. Clin. Invest.99, 789–798 (1997).
   PubMed Web of Science ®Google Scholar
• Saveanu A, Gunz G, Dufour H et al. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas. J. Clin. Endocrinol. Metab.86, 140–145 (2001).
   PubMed Web of Science ®Google Scholar
• Tulipano G, Bonfanti C, Milani G et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro. Neuroendocrinology73, 344–351 (2001).
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Lewis I, Albert R et al. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat. Rev. Drug Discov.2, 999–1017 (2003).
   PubMed Web of Science ®Google Scholar
• Florio T, Morini M, Villa V et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology144, 1574–1584 (2003).
   PubMed Web of Science ®Google Scholar
• Adams RL, Adams IP, Lindow SW et al. Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium. Br. J. Cancer92, 1493–1498 (2005).
   PubMed Web of Science ®Google Scholar
• Watson JC, Balster DA, Gebhardt BM et al. Growing vascular endothelial cells express somatostatin subtype 2 receptors. Br. J. Cancer85, 266–272 (2001).
   PubMed Web of Science ®Google Scholar
• Sall JW, Klisovic DD, O’Dorisio MS, Katz SE. Somatostatin inhibits IGF-1 mediated induction of VEGF in human retinal pigment epithelial cells. Exp. Eye Res.79, 465–476 (2004).
   PubMed Web of Science ®Google Scholar
• Cascinu S, Del Ferro E, Ligi M et al. Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patients. Cancer Invest.19, 8–12 (2001).
   PubMed Web of Science ®Google Scholar
• Mentlein R, Eichler O, Forstreuter F, Held-Feindt J. Somatostatin inhibits the production of vascular endothelial growth factor in human glioma cells. Int. J. Cancer92, 545–550 (2001).
   PubMed Web of Science ®Google Scholar
• Lopez F, Esteve JP, Buscail L et al. The tyrosine phosphatase SHP-1 associates with the sst2 somatostatin receptor and is an essential component of sst2-mediated inhibitory growth signaling. J. Biol. Chem.272, 24448–24454 (1997).
   PubMed Web of Science ®Google Scholar
• Cattaneo MG, Taylor JE, Culler MD et al. Selective stimulation of somatostatin receptor subtypes: differential effects on Ras/MAP kinase pathway and cell proliferation in human neuroblastoma cells. FEBS Lett.481, 271–276 (2000).
   PubMedGoogle Scholar
• Lahlou H, Guillermet J, Hortala M et al. Molecular signaling of somatostatin receptors. Ann NY Acad. Sci.1014, 121–131 (2004).
   PubMed Web of Science ®Google Scholar
• Arena S, Pattarozzi A, Corsaro A et al. Somatostatin receptor subtype-dependent regulation of nitric oxide release: involvement of different intracellular pathways. Mol. Endocrinol.19, 255–267 (2005).
   PubMedGoogle Scholar
• Lahlou H, Fanjul M, Pradayrol L et al. Restoration of functional gap junctions through internal ribosome entry site-dependent synthesis of endogenous connexins in density-inhibited cancer cells. Mol. Cell Biol.25, 4034–4045 (2005).
   PubMed Web of Science ®Google Scholar
• Guillermet J, Saint-Laurent N, Rochaix P et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl Acad. Sci. USA100, 155–160 (2003).
   PubMed Web of Science ®Google Scholar
• Teijeiro R, Rios R, Costoya JA et al. Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol. Biochem.12, 31–38 (2002).
   PubMed Web of Science ®Google Scholar
• Brazeau P, Vale W, Burgus R et al. Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science179, 77–79 (1973).
   PubMed Web of Science ®Google Scholar
• Bauer W, Briner U, Doepfner W et al. SMS 201–995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci.31, 1133–1140 (1982).
   PubMed Web of Science ®Google Scholar
• Pless J. The history of somatostatin analogs. J. Endocrinol. Invest.28, 1–4 (2005).
   PubMedGoogle Scholar
• Lancranjan I, Bruns C, Grass P et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism45, 67–71 (1996).
   PubMed Web of Science ®Google Scholar
• Caron P, Morange-Ramos I, Cogne M, Jaquet P. Three year follow-up of acromegalic patients treated with intramuscular slow-release lanreotide. J. Clin. Endocrinol. Metab.82, 18–22 (1997).
   PubMed Web of Science ®Google Scholar
• Cai RZ, Szoke B, Lu R et al. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. Proc. Natl Acad. Sci. USA83, 1896–1900 (1986).
   PubMed Web of Science ®Google Scholar
• Nagy A, Schally AV, Halmos G et al. Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl Acad. Sci. USA95, 1794–1799 (1998).
   PubMed Web of Science ®Google Scholar
• Krenning EP, Kwekkeboom DJ, Bakker WH et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med.20, 716–731 (1993).
   PubMedGoogle Scholar
• Forrer F, Valkema R, Kwekkeboom DJ et al. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab.21, 111–129 (2007).
   PubMed Web of Science ®Google Scholar
• Caron P, Beckers A, Cullen DR et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J. Clin. Endocrinol. Metab.87, 99–104 (2002).
   PubMed Web of Science ®Google Scholar
• Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N. Engl. J. Med.334, 246–254 (1996).
   PubMed Web of Science ®Google Scholar
• Kvols LK, Moertel CG, O’Connell MJ et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N. Engl. J. Med.315, 663–666 (1986).
   PubMed Web of Science ®Google Scholar
• Tomassetti P, Migliori M, Corinaldesi R, Gullo L. Treatment of gastroenteropancreatic neuroendocrine tumours with octreotide LAR. Aliment. Pharmacol. Ther.14, 557–560 (2000).
   PubMed Web of Science ®Google Scholar
• Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann. Oncol.10(Suppl. 2), S31–S38 (1999).
   Google Scholar
• Maton PN. The use of the long-acting somatostatin analogue, octreotide acetate, in patients with islet cell tumors. Gastroenterol. Clin. North Am.18, 897–922 (1989).
   PubMedGoogle Scholar
• Panzuto F, Di Fonzo M, Iannicelli E et al. Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann. Oncol.17, 461–466 (2006).
   PubMed Web of Science ®Google Scholar
• O’Dorisio TM, Mekhjian HS, Gaginella TS. Medical therapy of VIPomas. Endocrinol. Metab. Clin. North Am.18, 545–556 (1989).
   PubMed Web of Science ®Google Scholar
• Rosenbaum A, Flourie B, Chagnon S et al. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature. Digestion42, 116–120 (1989).
   PubMedGoogle Scholar
• Ruszniewski P, Laucournet H, Elouaer-Blanc L et al. Long-acting somatostatin (SMS 201-995) in the management of Zollinger–Ellison syndrome: evidence for sustained efficacy. Pancreas3, 145–152 (1988).
   PubMedGoogle Scholar
• Rubin J, Ajani J, Schirmer W et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol.17, 600–606 (1999).
   PubMed Web of Science ®Google Scholar
• Ch’ng JL, Christofides ND, Kraenzlin ME et al. Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. Am. J. Med.79, 135–138 (1985).
   PubMed Web of Science ®Google Scholar
• Barhoum M, Hutchins L, Fonseca VA. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide. Am. J. Med. Sci.318, 203–205 (1999).
   PubMed Web of Science ®Google Scholar
• Seufert J, Ebert K, Muller J et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med.345, 1883–1888 (2001).
   PubMed Web of Science ®Google Scholar
• De Herder WW, Lamberts SW. Octapeptide somatostatin-analogue therapy of Cushing’s syndrome. Postgrad. Med. J.75, 65–66 (1999).
   PubMedGoogle Scholar
• Arnold R, Simon B, Wied M. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review. Digestion62(Suppl. 1), 84–91 (2000).
   PubMedGoogle Scholar
• Saltz L, Trochanowski B, Buckley M et al. Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer72, 244–248 (1993).
   PubMed Web of Science ®Google Scholar
• Welin SV, Janson ET, Sundin A et al. High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours. Eur. J. Endocrinol.151, 107–112 (2004).
   PubMed Web of Science ®Google Scholar
• Faiss S, Rath U, Mansmann U et al. Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion60, 469–476 (1999).
   PubMed Web of Science ®Google Scholar
• Granberg D, Jacobsson H, Oberg K et al. Regression of a large malignant gastrinoma on treatment with Sandostatin LAR: a case report. Digestion77, 92–95 (2008).
   PubMedGoogle Scholar
• Plockinger U, Wiedenmann B. Neuroendocrine tumors. Biotherapy. Best Pract. Res. Clin. Endocrinol. Metab.21, 145–162 (2007).
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ et al. Octreotide versus octreotide plus interferon-α in endocrine gastroenteropancreatic tumors: a randomized trial. Clin. Gastroenterol. Hepatol.3, 761–771 (2005).
   PubMed Web of Science ®Google Scholar
• Arnold R. Placebo-controlled, double-blind, prospective randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. Presented at: ASCO 2009 Gastrointestinal Cancers Symposium. San Francisco, CA, USA, 15–17 January 2009 (Abstract 121).
   Google Scholar
• Hussaini SH, Murphy GM, Kennedy C et al. The role of bile composition and physical chemistry in the pathogenesis of octreotide-associated gallbladder stones. Gastroenterology107, 1503–1513 (1994).
   PubMed Web of Science ®Google Scholar
• Bigg-Wither GW, Ho KK, Grunstein RR et al. Effects of long term octreotide on gall stone formation and gall bladder function. BMJ304, 1611–1612 (1992).
   PubMedGoogle Scholar
• Trendle MC, Moertel CG, Kvols LK. Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors. Cancer79, 830–834 (1997).
   PubMed Web of Science ®Google Scholar
• Plockinger U, Dienemann D, Quabbe HJ. Gastrointestinal side-effects of octreotide during long-term treatment of acromegaly. J. Clin. Endocrinol. Metab.71, 1658–1662 (1990).
   PubMed Web of Science ®Google Scholar
• Plockinger U, Perez-Canto A, Emde C et al. Effect of the somatostatin analog octreotide on gastric mucosal function and histology during 3 months of preoperative treatment in patients with acromegaly. Eur. J. Endocrinol.139, 387–394 (1998).
   PubMedGoogle Scholar
• Behrns KE, Sarr MG. Diagnosis and management of gastric emptying disorders. Adv. Surg.27, 233–255 (1994).
   PubMedGoogle Scholar
• Oberg K, Kvols L, Caplin M et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann. Oncol.15, 966–973 (2004).
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon-α, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J. Clin. Oncol.21, 2689–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Yao JC, Phan AT, Chang DZ et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a Phase II study. J. Clin. Oncol.26, 4311–4318 (2008).
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg K, Glusman JE et al. The SOM230 Carcinoid Study Group. Safety and efficacy of pasireotide (SOM230) in patients with metastatic carcinoid tumors refractory or resistant to Octreotide LAR: results of a Phase II study. In: ASCO Annual Meeting Proceedings Part I24(18 Suppl.) (2006) (Abstract 4082).
   Google Scholar
• Jaquet P, Gunz G, Saveanu A et al. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide. J. Endocrinol. Invest.28, 21–27 (2005).
   PubMedGoogle Scholar
• Fjallskog ML, Ludvigsen E, Stridsberg M, Oberg K, Eriksson B, Janson ET. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors. Med. Oncol.20(1), 59–67 (2003).
   PubMedGoogle Scholar
• Kulaksiz H, Eissele R, Rossler D et al. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut50(1), 52–60 (2002).
   PubMed Web of Science ®Google Scholar
• Papotti M, Bongiovanni M, Volante M et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch.440(5), 461–475 (2002).
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur. J. Endocrinol.146, 707–716 (2002).
   PubMed Web of Science ®Google Scholar